Kandepres (Candesartan Cilexetil)

Candesartan cilexetil is converted in the body to candesartan, which selectively blocks AT1 receptors for angiotensin II. This inhibition prevents vasoconstriction and aldosterone release, leading to blood‑vessel relaxation, reduced sodium retention, and lower blood pressure.

The appropriate dose of Kandepres is determined by a qualified prescriber based on the individual’s clinical condition, response to therapy, and any relevant laboratory values. Patients should follow the dosing instructions provided by their healthcare professional.

Kandepres is classified as pregnancy category D, indicating evidence of fetal risk, and it is contraindicated during pregnancy. Limited data are available for breastfeeding; therefore, use is generally not recommended unless the benefit outweighs the potential risk.

To order Kandepres, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Kandepres (candesartan) offers a once‑daily dosing schedule and a long half‑life, providing consistent blood‑pressure control. Compared with other ARBs such as losartan, candesartan generally has a higher receptor affinity and may achieve greater reductions in blood pressure at equivalent doses, though individual response can vary.

Kandepres should be stored at ambient temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and do not use it after the expiry date printed on the label.

Kandepres is taken orally, usually once daily, with or without food. The tablet should be swallowed whole with a glass of water. Patients should not crush or chew the tablet unless specifically instructed by a healthcare professional.

The most serious risks include hyperkalemia (elevated blood potassium), acute kidney injury, severe hypotension, and angioedema, which can be life‑threatening. Patients should be monitored for these events, especially when starting therapy or adjusting the dose.

Kandepres should not be used by individuals who are pregnant, have a known hypersensitivity to candesartan or any component of the formulation, or have severe hepatic impairment. Caution is also advised in patients with severe renal dysfunction or a history of angioedema.